Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2

Eskens, 2004, Angiogenesis inhibitors in clinical development; where are we now and where are we going?, Br. J. Cancer, 90, 1, 10.1038/sj.bjc.6601401 Kwitkowski, 2010, FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma, Oncologist, 15, 428, 10.1634/theoncologist.2009-0178 Abhinand, 2016, VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis, J. Cell Commun. Signal., 10, 347, 10.1007/s12079-016-0352-8 La, 2008, Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis, J. Med. Chem., 51, 1695, 10.1021/jm701129j Pereira, 2019, Magnetoliposomes containing calcium ferrite nanoparticles for applications in breast cancer therapy, Pharmaceutics., 11, 477, 10.3390/pharmaceutics11090477 Rajagopalan, 2013, Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors, J. Enzyme Inhib. Med. Chem., 28, 1236, 10.3109/14756366.2012.729826 Elsayed, 2019, Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity, Bioorg. Chem., 82, 340, 10.1016/j.bioorg.2018.10.071 Musumeci, 2012, Vascular endothelial growth factor (VEGF) receptors: Drugs and new inhibitors, J. Med. Chem., 55, 10797, 10.1021/jm301085w Shahin, 2014, Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold, Bioorg. Chem., 56, 16, 10.1016/j.bioorg.2014.05.010 Aziz, 2016, Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents, Sci. Rep., 6, 24460, 10.1038/srep24460 Regan, 2003, The kinetics of binding to p38 MAP kinase by analogues of BIRB 796, Bioorganic Med. Chem. Lett., 13, 3101, 10.1016/S0960-894X(03)00656-5 Wilhelm, 2004, BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res., 64, 7099, 10.1158/0008-5472.CAN-04-1443 Mckenna, Application Data (60) Provisional application No, 2004. https://patents.google.com/patent/US20070020704A1/en (accessed December 23, 2020). Harris, 2008, Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor, J. Med. Chem., 51, 4632, 10.1021/jm800566m Inoue, 2012, Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice, Clin. Cancer Res., 18, 3924, 10.1158/1078-0432.CCR-11-2041 Sonpavde, 2008, Axitinib for renal cell carcinoma, Expert Opin. Invest. Drugs, 17, 741, 10.1517/13543784.17.5.741 Yakes, 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol. Cancer Ther., 10, 2298, 10.1158/1535-7163.MCT-11-0264 Al-Abd, 2017, Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review, J. Adv. Res., 8, 591, 10.1016/j.jare.2017.06.006 Khalid, 2016, Natural products against cancer angiogenesis, Tumor Biol., 37, 14513, 10.1007/s13277-016-5364-8 D.B. Mendel, A. Douglas Laird, X. Xin, S.G. Louie, J.G. Christensen, G. Li, R.E. Schreck, T.J. Abrams, T.J. Ngai, L.B. Lee, L.J. Murray, J. Carver, E. Chan, K.G. Moss, J.Ö. Haznedar, J. Sukbuntherng, R.A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, J.M. Cherrington, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship, Clin. Cancer Res. 9 (2003) 327–337. https://pubmed.ncbi.nlm.nih.gov/12538485/ (accessed July 31, 2020). Peng, 2017, VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012–2016), Expert Opin. Ther. Pat., 27, 987, 10.1080/13543776.2017.1344215 Liu, 2014, Optimization of GPR40 agonists for type 2 diabetes, ACS Med. Chem. Lett., 5, 517, 10.1021/ml400501x Karabasanagouda, 2009, Synthesis of some new pyrazolines and isoxazoles carrying 4-methylthiophenyl moiety as potential analgesic and antiinflammatory agents, Indian J. Chem. - Sect. B Org, Med. Chem., 48, 430 Mączyński, 2016, Anti-inflammatory properties of an isoxazole derivative - MZO-2, Pharmacol. Reports., 68, 894, 10.1016/j.pharep.2016.04.017 Loh, 2010, Inhibition of HIV-1 replication by isoxazolidine and isoxazole sulfonamides, Chem. Biol. Drug Des., 75, 461, 10.1111/j.1747-0285.2010.00956.x Eccles, 2008, NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis, Cancer Res., 68, 2850, 10.1158/0008-5472.CAN-07-5256 Solárová, 2015, Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review), Int. J. Oncol., 46, 907 Shin, 2005, Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation, J. Biol. Chem., 280, 41439, 10.1074/jbc.M507209200 Shin, 2008, KRIBB3, a novel microtubule inhibitor, induces mitotic arrest and apoptosis in human cancer cells, Biochem. Pharmacol., 75, 383, 10.1016/j.bcp.2007.08.027 Çalışkan, 2018, Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents, J. Enzyme Inhib. Med. Chem., 33, 1352, 10.1080/14756366.2018.1504041 Moloudi, 2018, Synthesis of 2,3-dicyanopyrazine and ethyl 5-amino-4,6-dicyanobiphenyl-3-carboxylate derivatives from ethyl aroylpyruvates, Heterocycl. Commun., 24, 99, 10.1515/hc-2017-0190 Voskienė, 2009, Cyclization of chalcones to isoxazole and pyrazole derivatives, Chem. Heterocycl. Compd., 45, 1485, 10.1007/s10593-010-0455-8 Dawood, 2011, Synthesis, anti-HSV-1, and cytotoxic activities of some new pyrazole- and isoxazole-based heterocycles, Med. Chem. Res., 20, 912, 10.1007/s00044-010-9420-4 Agrawal, 2019, Novel isoxazole derivatives as potential antiparkinson agents: synthesis, evaluation of monoamine oxidase inhibitory activity and docking studies, Med. Chem. Res., 28, 1488, 10.1007/s00044-019-02388-4 Berndt, 1982, Reaction of Acyl Azide and Amines. Kinetics and Mechanism, J. Org. Chem., 47, 4167, 10.1021/jo00142a033 Li, 2008, Iodobenzene dichloride in combination with sodium azide for the effective synthesis of carbamoyl azides from aldehydes, Synthesis (Stuttg)., 2008, 2589, 10.1055/s-2008-1067196 Techniques, 1996, Elsevier Mata, 2020, Acyl azide generation and amide bond formation in continuous-flow for the synthesis of peptides, React. Chem. Eng., 5, 645, 10.1039/D0RE00034E Comprehensive Organic Functional Group Transformations;, 09 (2007). https://books.google.com.eg/books?id=cAm7rA_D25wC&pg=PA266&lpg=PA266&dq=Amides+acid+becomes+activated%5C+without+itself+attacking+the+diimide%5B+For+a+primary+amine+at+least%5C+there+is+a+possibility+that+the+amine+could+become+part+of+a+mixed+diimide+%22 (accessed July 31, 2020). Ghosh, 2018, The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry, ChemMedChem, 13, 2351, 10.1002/cmdc.201800518 Ghosh, 2018, The Curtius rearrangement: Mechanistic insight and recent applications in natural product syntheses, Org. Biomol. Chem., 16, 2006, 10.1039/C8OB00138C Augustine, 2011, Propylphosphonic anhydride (T3P®)-mediated one-pot rearrangement of carboxylic acids to carbamates, Synthesis (Stuttg)., 2011, 1477, 10.1055/s-0030-1259964 Stopeck, 2002, Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies, Clin. Cancer Res., 8, 2798 Demirbas, 2004, Synthesis and antimicrobial activities of some new 1-(5-phenylamino-[1,3,4] thiadiazol-2-yl)methyl-5-oxo-[1,2,4]triazole and 1-(4-phenyl-5-thioxo-[1,2,4] triazol-3-yl)methyl-5-oxo- [1,2,4]triazole derivatives, Eur. J. Med. Chem., 39, 793, 10.1016/j.ejmech.2004.06.007 Patorski, 2013, Synthesis and conformational assignment of N-(E)- stilbenyloxymethylenecarbonyl-substituted hydrazones of acetone and o-(m-and p-) chloro- (nitro-) benzaldehydes by means of 1H and 13C NMR spectroscopy, J. Spectrosc., 1, 12 Journals, 2008, JNCI Journal of the National Cancer Institute Way to Better DNA, Ann. Intern. Med., 37, 1 Peng, 2014, Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma, Hepatology, 60, 1264, 10.1002/hep.27236 Xiang, 2014, Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET, Clin. Cancer Res., 20, 2959, 10.1158/1078-0432.CCR-13-2620 Rashed, 2020, Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview, J. Egypt. Natl. Canc. Inst., 32, 1, 10.1186/s43046-020-0016-x Mosmann, 1983, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65, 55, 10.1016/0022-1759(83)90303-4 Hu, 2003, Anticancer therapy targeting the apoptotic pathway, Lancet Oncol., 4, 721, 10.1016/S1470-2045(03)01277-4 Maher, 2019, Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis, J. Enzyme Inhib. Med. Chem., 34, 532, 10.1080/14756366.2018.1564046 Bahuguna, 2017, MTT assay to evaluate the cytotoxic potential of a drug, Bangladesh J. Pharmacol., 12, 115, 10.3329/bjp.v12i2.30892 El-Miligy, 2018, Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies, Futur. Sci. OA., 4, FSO252, 10.4155/fsoa-2017-0075 Sobhy, 2019, 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation, Bioorg. Chem., 89, 102988, 10.1016/j.bioorg.2019.102988 Wang, 2019, Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation, Chem. Biol. Drug Des., 93, 934, 10.1111/cbdd.13493 Protein Data Bank, RCSB PDB: Homepage, Rcsb Pdb. (2019) 1. https://www.rcsb.org/ (accessed July 31, 2020). Daina, 2017, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep., 7, 1, 10.1038/srep42717 Alley, 1988, Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay, Cancer Res., 48, 584 Grever, 1992, The National Cancer Institute: Cancer drug discovery and development program, Semin. Oncol., 19, 622 Boyd, 1995, Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen, Drug Dev. Res., 34, 91, 10.1002/ddr.430340203 El-Meligie, 2017, Design, synthesis and cytotoxic activity of certain novel chalcone analogous compounds, Eur. J. Med. Chem., 126, 52, 10.1016/j.ejmech.2016.09.099 AbdElhameid, 2018, Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors, J. Enzyme Inhib. Med. Chem., 33, 1472, 10.1080/14756366.2018.1503654 Tolba, 2013, Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells, IUBMB Life, 65, 716, 10.1002/iub.1188 Abdelhaleem, 2018, Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7, Eur. J. Med. Chem., 143, 1807, 10.1016/j.ejmech.2017.10.075 Sharma, 2015, Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors - review of assay methodologies and perspectives, Biomed. Chromatogr., 29, 803, 10.1002/bmc.3370 Fontanella, 2014, Clinical advances in the development of novel VEGFR2 inhibitors, Ann. Transl. Med., 2, 123 Hassan, 2019, Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors, Eur. J. Med. Chem., 184, 111747, 10.1016/j.ejmech.2019.111747